Every two seconds somebody in the world needs blood.

Only in U.S. 36 thousand units of red blood cells are transfused every day. The need for donor blood increases rapidly which will result in 3 million units of blood deficit by the year 2030.  An artificial blood supply could cover this shortage which will turn into saved lives. For this reason NanoSanguis team is developing innovative and safe red blood cells substitute which can alternate to natural blood.

About us

NanoSanguis is an unique niche where the advanced science meets practical application experience and professional business. The company has its origin in Warsaw University of Technology – the cluster of excellence in polish innovative commercialization. We have started as a team of PhD candidates developing technology of oxygen therapeutics. In December 2015, together with two VC capitals – Start Venture Poland and Giza Polish Ventures, we founded NanoSanguis to bring to the market first safe and effective red blood cell substitute.


NanoSanguis mission is to give safe red blood cell substitute every human in need regardless of their origin, social status and religious beliefs.


We strive to fulfill our mission through the use of scientific and business competencies of our team to commercialize our unique know-how of producing the synthetic oxygen carrier. We will bring to the market the first effective substitute of natural blood for transfusions and organs transport.


Despite of the fact that donor blood transfusions saved many lives, they still have not overcame serious problems. The short shelf life seems to be the most critical. 1.3 million pints of donated blood spoil every year since blood only has a 40 day shelf life. In NanoSanguis we developed the technology for producing synthetic oxygen carrier which is stable for at least one year of storage. Our blood substitute is based on full physiological, buffered fluid composed of balanced minerals compatible with human organism enriched with the source of energy and biomimic microcapsules containing oxygen.


The oxygen therapeutic produced by our team has unique features:

  • nontoxic and bio-inert properties (it does not interfere in metabolic and enzymatic pathways),

  • effective oxygen transport capacity (it can carry several times more oxygen per cubic centimeter than blood, and load/unload oxygen 2 times faster than hemoglobin),

  • unlimited manufacturing capabilities,

  • compatible with all blood types.

Since our product is synthesized in sterile laboratory conditions it can challenge other disadvantage of natural blood- risk of viruses infections. It is critical issue especially in Africa, where in 2004, about 1.2 million units of blood were collected from donors who are considered at high risk for transmitting HIV, hepatitis B or hepatitis C. Moreover, our artificial blood substitute can overcome the ethical issues and religious obstacles connected with natural blood transfusions.

In NanoSanguis we have also recognised another great field of potential application of our oxygen carrier- the transport of organs for transplantations. There is a huge need of improving the organs transport systems. Because of non physiological conditions of transport, many transplantations end with organ failure. Especially in countries where the distances between hospitals and cities are big and the transport lasts hours (U.S.), this problem seems to be crucial. In NanoSanguis we want to apply our oxygen therapeutic to organ transport systems not only to provide the physiological conditions but also to give to the organ the ability for regeneration before transplant.

Our team

Agata Stefanek

Agata Stefanek

CEO, founder, researcher

Biotechnologist. PhD candidate on Warsaw University of Technology at the Faculty of Chemical and Process Engineering. Specialist in tissue engineering, cell encapsulation, artificial organs designing. Strong experience in project management earned by leading National Science Centre’s projects. Mountain guide, sailor; interested in wooden architecture and iconography.

Tomasz Ciach

Tomasz Ciach


Nanotechnology expert.  Professor at the Faculty of Chemical and Processing Engineering, Warsaw University of Technology, head of the Biotechnology and Bioprocessing Division. Author of two technologies that are already in production stage, 12 granted patents and over 50 publications. Founder of BioMedLab research group, consultant in numerous companies (AstraZeneca, Procter and Gamble, Reckit, Adamed, Balton, Galmed). He gives rare, but already brilliant example of how brave ideas become socially and financially valuable.

Kamil Kopeć

Kamil Kopeć

COO, Member of the Board

Biotechnologist.  PhDc at Warsaw University of Technology. Member of BioMedical Engineering Laboratory at the Faculty of Chemical and Process Engineering WUT. Specialist in the field of hydrogel and antibacterial coatings. Participant in many courses of entrepreneurship and Life Science projects commercialization.

Marek Borzestowski

Marek Borzestowski

President of the Supervisory Board

President of Supervisory Board and co-founder of Startup Hub Poland, which was his idea. Entrepreneur, manager and founder of numerous Internet companies with over 15 years of experience as a co-owner and board member in leading Polish web-, IT-, and e-commerce companies: Wirtualna Polska, InteliWISE, Gruper, Centrum Nowych Technologii. Being a managing partner in GPV Marek is responsible for new-technology investments, development and mentoring (Nano Velos, Audioteka, Vivid Games).

Maciej Sadowski

Maciej Sadowski

Memmber of the Supervisory Board

Co-founder and President of the Board in Startup Hub Poland.Manager in innovative ICT projects in early and mature stage of development. Seed and startup investment manager. Member of the Committee on New Technologies and Innovations to the Polish Chamber of Commerce. Member of the National Development Council to the President of the Republic of Poland. 

Paweł Ciach

Paweł Ciach

Member of the Supervisory Board

Diplomat , a specialist in the field of Marketing, Media Relations, Strategic Communications and Marketing Communications. He served as a President of the Foundation for the Disabled and worked as Advertising Director of Data Telecommunications Systems and TV Center.

Adam Kiciak

Adam Kiciak

Preclinical studies Consultant, PhD

Surgeon, specialized in both colorectal and bariatric surgery as well as phlebology. Worked as medical advisor in PFIZER Inc., CEO in BIOIVEST 2005 SA, a small pharmaceutical company for humans and productive animals and Vice-President for R&D in BIOLEK Ltd (BIOTON SA GROUP). Co-inventor of patent and co-author of the marketed success of the product widely used in gastroenterology.

Joanna Graffstein

Joanna Graffstein

Product Engineer

Biotechnologist. Studies at Warsaw University of Technology (Faculty of Chemistry) and University of Warsaw (Faculty of Biology). Specialist in an artificial oxygen carriers. Experience in working on perfluorocarbon emulsion. Interested in horse riding, mountain climbing, literature of 20th century.

Aleksandra Nowak

Aleksandra Nowak

Quality Controler

Biotechnologist, graduated from Cracow University of Technology, master studies at Warsaw University of Technology with major in Biotechnology in cosmetic and pharmaceutical field. Experienced in working at R&D departments at various companies. Expert in dialysis and filtration processes, responsible for optimization of final product purification. Involved in cell cultures and its encapsulation.

Katarzyna Krasucka

Katarzyna Krasucka

Office Manager

Biomedical Engineer, graduated from Mechatronic Department of Warsaw University of Technology, Mechanical Department of Lublin University of Technology and Medical Department of Medical University of Lublin.

Wojciech Frąckowiak

Wojciech Frąckowiak

Microfluidic Engineer

Chemical and process engineer. Graduated from West Pomeranian University of Technology and Pomeranian Medical University. Graduate student with a major in Bioengineering at Warsaw University of Technology. Interested in human physiology and artificial organs designing. Movie editor and history enthusiast.

Katarzyna Łęczycka-Wilk

Katarzyna Łęczycka-Wilk

Organic chemist

Synthesis Specialist, PhD candidate on the Institute of Organic Chemistry, Polish Academy of Sciences. Specializes in the field of organic and supramolecular chemistry. Current research interests are focused on development of new synthetic pathways in carbohydrate chemistry, especially explore the chemistry of macrocyclic sucrose derivatives.

Sylwia Czarnocka-Śniadała

Sylwia Czarnocka-Śniadała

Organic chemist, PhD

Chemist Researcher, PhD at Warsaw University of Technology Faculty of Chemistry. Strong experienced in working at R&D, Quality Control and Production departments at various companies. Specialist in multi-step syntheses of heterocyclic compounds and pharmaceuticals, purification and analysis techniques. Interested in biotechnology and phytochemistry.

What we do?

oxygen carriers



blood transfusions, transplantations


artificial blood, long-distance organs transport

Contact us


NIP: 7010537389

REGON:  363505173



Ludwika Waryńskiego 1
00-645 Warsaw, Poland

EuroNanoMed III

Project “Nanosystems conjugated with antibody fragments for treating brain infections” co-financed by the National Centre for Research and Development under the EuroNanoMed III Joint Transnational Call for Proposal (2018) for „European Innovative Research & Technological Development Projects in Nanmedicine”


Project co-financed by the European Regional Development Fund under the Operational Programme Innovative Economy.


Project co-financed by the National Centre for Research and Development under the Smart Growth Operational Programme 2014-2020.


Project co-financed by the the European Regional Development Fund under the Mazovian Regional Operational Program for the years 2014-2020.